Haleon (NYSE:HLN) Upgraded to Buy at Wall Street Zen

Haleon (NYSE:HLN) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

HLN has been the subject of several other reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Argus raised Haleon to a “strong-buy” rating in a research report on Tuesday. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $12.33.

Haleon Price Performance

HLN opened at $10.08 on Friday. The firm has a market cap of $44.88 billion, a PE ratio of 25.83 and a beta of 0.18. The stock has a 50-day moving average price of $10.53 and a 200-day moving average price of $9.88. Haleon has a 1 year low of $8.71 and a 1 year high of $11.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71.

Institutional Trading of Haleon

Several large investors have recently added to or reduced their stakes in the business. IHT Wealth Management LLC raised its position in Haleon by 6.9% in the fourth quarter. IHT Wealth Management LLC now owns 16,205 shares of the company’s stock worth $164,000 after acquiring an additional 1,049 shares during the period. National Bank of Canada FI boosted its stake in shares of Haleon by 6.7% during the 3rd quarter. National Bank of Canada FI now owns 17,385 shares of the company’s stock worth $156,000 after acquiring an additional 1,099 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in shares of Haleon by 4.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 24,744 shares of the company’s stock valued at $250,000 after acquiring an additional 1,100 shares during the period. Cary Street Partners Financial LLC grew its position in shares of Haleon by 20.1% during the 2nd quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock valued at $69,000 after acquiring an additional 1,113 shares during the period. Finally, Cardinal Capital Management increased its stake in shares of Haleon by 2.4% in the 3rd quarter. Cardinal Capital Management now owns 48,085 shares of the company’s stock worth $431,000 after purchasing an additional 1,116 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.